Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival BioSpaceIndirect comparisons between BridgeBio's Attruby and Pfizer's tafamidis products showed a numerical survival benefit with the biotech's drug.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA turns to old drugs to address new diseases, persistent medical needsNext: EU agrees plan to tackle essential medicine shortages Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
